126 related articles for article (PubMed ID: 1718466)
1. Heparin cofactor II: an acute phase reactant in patients with deep vein thrombosis.
Toulon P; Vitoux JF; Fiessinger JN; Sicard D; Aiach M
Blood Coagul Fibrinolysis; 1991 Jun; 2(3):435-9. PubMed ID: 1718466
[TBL] [Abstract][Full Text] [Related]
2. Increased heparin cofactor II levels in women taking oral contraceptives.
Toulon P; Bardin JM; Blumenfeld N
Thromb Haemost; 1990 Nov; 64(3):365-8. PubMed ID: 2096488
[TBL] [Abstract][Full Text] [Related]
3. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis.
Villa P; Aznar J; Vaya A; España F; Ferrando F; Mira Y; Estellés A
Thromb Haemost; 1999 Sep; 82(3):1011-4. PubMed ID: 10494755
[TBL] [Abstract][Full Text] [Related]
4. [Heparin cofactor II (HCII) activity and antigen assay and their significance in thrombotic diseases].
Dai CW; Zhang GS
Zhonghua Xue Ye Xue Za Zhi; 2003 Sep; 24(9):452-4. PubMed ID: 14575585
[TBL] [Abstract][Full Text] [Related]
5. Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus.
Toulon P; Lamine M; Ledjev I; Guez T; Holleman ME; Sereni D; Sicard D
Thromb Haemost; 1993 Nov; 70(5):730-5. PubMed ID: 8128426
[TBL] [Abstract][Full Text] [Related]
6. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan.
Tanaka KA; Szlam F; Vinten-Johansen J; Cardin AD; Levy JH
Thromb Haemost; 2005 Oct; 94(4):808-13. PubMed ID: 16270635
[TBL] [Abstract][Full Text] [Related]
7. Heparin cofactor II levels are increased by the use of combined oral contraceptives.
Mackie IJ; Segal H; Burren T; Gallimore M; Walshe KJ; Robinson G; Machin SJ
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):647-51. PubMed ID: 2133244
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Lopaciuk S; Bykowska K; Kopeć M
Pol J Pharmacol; 1996; 48(1):109-11. PubMed ID: 9112638
[TBL] [Abstract][Full Text] [Related]
9. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome.
Toulon P; Gandrille S; Remy P; Chadeuf G; Jouvin MH; Aiach M
Nephron; 1992; 60(2):176-80. PubMed ID: 1553002
[TBL] [Abstract][Full Text] [Related]
10. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
Tran TH; Duckert F
Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
[TBL] [Abstract][Full Text] [Related]
11. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction.
Huang SS; Huang PH; Chen YH; Sung SH; Chiang KH; Chen JW; Lin SJ
Coron Artery Dis; 2008 Dec; 19(8):597-602. PubMed ID: 18971786
[TBL] [Abstract][Full Text] [Related]
12. Two cases of inherited triple deficiency in a large kindred with thrombotic diathesis and deficiencies of antithrombin III, heparin cofactor II, protein C and protein S.
Jobin F; Vu L; Lessard M
Thromb Haemost; 1991 Sep; 66(3):295-9. PubMed ID: 1836072
[TBL] [Abstract][Full Text] [Related]
13. The role of heparin cofactor II in the modulation of hemostasis.
Salem HH; Thompson EA
Dev Biol Stand; 1987; 67():67-72. PubMed ID: 3301469
[TBL] [Abstract][Full Text] [Related]
14. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.
Prandoni P; Villalta S; Bagatella P; Rossi L; Marchiori A; Piccioli A; Bernardi E; Girolami B; Simioni P; Girolami A
Haematologica; 1997; 82(4):423-8. PubMed ID: 9299855
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations.
Tiede A; Tait RC; Shaffer DW; Baudo F; Boneu B; Dempfle CE; Horellou MH; Klamroth R; Lazarchick J; Mumford AD; Schulman S; Shiach C; Bonfiglio LJ; Frieling JT; Conard J; von Depka M
Thromb Haemost; 2008 Mar; 99(3):616-22. PubMed ID: 18327412
[TBL] [Abstract][Full Text] [Related]
16. Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Toulon P; Moulonguet-Doleris L; Costa JM; Aiach M
Thromb Haemost; 1991 Jan; 65(1):20-4. PubMed ID: 2024235
[TBL] [Abstract][Full Text] [Related]
17. [Dynamic changes and localization of plasma heparin cofactor II before and after delivery in hypertensive pregnancy].
Chen X; Zhang G; Wang C
Zhonghua Xue Ye Xue Za Zhi; 1999 Sep; 20(9):468-70. PubMed ID: 11721410
[TBL] [Abstract][Full Text] [Related]
18. Further studies on the mechanism for the antithrombotic effects of naroparcil, an orally active thiozyloside compound.
Masson P; Theveniaux J; Coup D; Grégoire T; Vaillot M; Dupouy D; Sié P; Boneu B; Millet J
Thromb Haemost; 1999 Jun; 81(6):945-50. PubMed ID: 10404773
[TBL] [Abstract][Full Text] [Related]
19. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
Levine MN; Hirsh J; Gent M; Turpie AG; Weitz J; Ginsberg J; Geerts W; LeClerc J; Neemeh J; Powers P
Thromb Haemost; 1995 Aug; 74(2):606-11. PubMed ID: 8584992
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation.
Ascani A; Iorio A; Agnelli G
Blood Coagul Fibrinolysis; 1999 Jul; 10(5):291-5. PubMed ID: 10456621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
